When Does the Mounjaro Patent Expire? UK Guide (October 2026)

01 · The core answer

Mounjaro patent expiry: what is known

The honest answer is that the tirzepatide patent is not expected to lapse for several years, and nobody can name the day a UK pharmacy will dispense a generic version. Pages that quote a single confident date are usually repeating one projection. A patent is only one layer of protection, and the others can run longer.

Eli Lilly holds the protection and supplies the medicine. Mounjaro is the brand name for tirzepatide, a once-weekly injectable prescription medicine made by Eli Lilly. For deeper background on the company's position, see our guide to Eli Lilly's patent position.

02 · Why there is no simple date

The layers that decide when generics can launch

Several separate protections sit behind a medicine like this.

The practical lesson: the earliest headline date is rarely the date a patient can actually buy a generic. Our explainer on the Mounjaro patent explained covers the same layers in more detail.

03 · What to do next

Does this affect you today?

For most readers, no. If you are deciding whether to start treatment, a patent that lasts several more years is not a reason to hold off, because the licensed treatment is available now through regulated routes. If you want to see how a regulated private supply works, start with the Mounjaro pen prices and consultation page, where a starting 2.5mg pen is £169.99 at standard price, with current discounts shown live.

If you are weighing cost, remember that generic competition would be a future event with an uncertain size. Planning your treatment around a price drop that may be years away carries its own cost, because the condition you are treating does not pause. Our weight loss clinic page explains how a consultation works if you want to talk it through with a prescriber.

Related guide: When does glp 1 patent expire.

04 · Patents versus exclusivity

Patents versus exclusivity: why expiry is not a switch

A patent expiring does not mean cheaper copies appear the next morning. A patent gives a company the right to stop others making and selling a protected invention for a fixed term. That term starts running well before a medicine reaches patients, because the filing happens early in development. By the time a product is licensed and launched, a good part of the term has already been used up.

To compensate, many jurisdictions allow a supplementary protection certificate, which can extend protection for the active ingredient. This is why you will see different projected end dates in the UK and in Europe, and why articles disagree. Some quote the core patent, some include extensions, and some blend the two without saying so. When you read a date, ask which layer it describes.

Regulatory exclusivity is separate again. It relates to the safety and efficacy data submitted for approval. While it applies, a competitor cannot simply lean on the original company's data to win approval for a copy. It runs on its own clock and can end before or after the patent.

Then there are secondary patents. Companies often file additional patents around the pen device, the formulation and the way the medicine is manufactured. These do not always block every copy, but they can force a competitor to design around them, which takes time and investment. A new entrant has to prove its product is equivalent and safe, and for an injectable delivered in a pen, the device matters as much as the contents.

The takeaway is that a single quoted date is a floor, not a forecast. The earliest possible moment for competition is the end of the first protection to lapse, but the realistic moment is when the last relevant barrier falls and an alternative is licensed, manufactured at scale and supplied. Our page on the patent expiry guide walks through this reasoning with the same caution.

It is also worth being clear about who benefits from the confusion. Sellers of unlicensed products often cite upcoming patent expiry as if it already permitted copies today. It does not. Until the protection ends and a regulator approves an alternative, the only legitimate supply is the licensed product from the licence holder.

05 · Why generics take time

Why a generic does not follow immediately

Even after protection ends, a generic must clear several practical hurdles before UK patients can use it. Understanding these is the best defence against over-optimistic headlines.

The first hurdle is licensing. In the UK, a copy of a medicine needs its own marketing authorisation from the regulator. The company must show that its product matches the original in quality and performs equivalently. For a pen injector, that includes proving the device delivers the right dose reliably. Mounjaro comes as a pre-filled multi-dose pen (KwikPen) in six strengths: 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg.¹ A competitor would need to match that whole system or justify a different one, and pen design is a specialised engineering field.

The second hurdle is manufacturing. Making an injectable at the volume demanded by a global weight-management market is not trivial. Companies need validated production lines, cold-chain logistics and quality systems, and these take years to build. Demand for this class of medicine is large, so a new supplier would be entering a market where scale matters.

The third hurdle is the supply chain into pharmacies. Wholesalers, pharmacies and prescribers need to be ready, and prescribers need guidance about switching. Patients on an established regimen would not switch automatically. The licensed pen has set instructions for storage, use and disposal, set out in the patient information leaflet,¹³ and any alternative would carry its own.

Because of this, even optimistic observers expect a gap between patent expiry and meaningful generic supply. What is clear is that the sequence is: protection lapses, a copy is approved, a copy is made at scale, then pharmacies stock it.

One more point matters for patients. A generic would be required to contain the same active ingredient, but you would still need a prescription and a prescriber's review. Nothing about patent expiry turns a prescription-only medicine into something you can buy freely. That regulatory status is set by safety considerations, not by patents.

06 · What tirzepatide is

What is being protected: tirzepatide

To see why the protection matters commercially, it helps to know what the medicine does. Mounjaro is the brand name for tirzepatide, a once-weekly injectable prescription medicine made by Eli Lilly. In the UK it is licensed for weight management in adults and for type 2 diabetes.¹

Tirzepatide is the first treatment of its kind to activate two natural gut-hormone receptors at once: GIP and GLP-1. Together these help regulate appetite, slow how quickly the stomach empties, and improve the way the body responds to insulin.¹¹¹ In practice, most people feel fuller sooner and less hungry between meals, which supports a reduced-calorie diet.

This dual action is what distinguishes Mounjaro from single-action medicines such as semaglutide (Wegovy/Ozempic). It is also why the patent position of tirzepatide is not the same as that of semaglutide. They are different molecules, filed and protected separately, and each has its own timeline.

The innovation is the reason for the long and layered protection. The company invested heavily in developing the compound, running large trials and building the manufacturing capacity to supply it. Patent law exists to reward that, for a limited period, in exchange for public disclosure and eventual competition.

For patients, the useful point is that the treatment is used alongside a reduced-calorie diet and increased physical activity, and it is prescribed after a clinical review. A change in who owns the patent would not change how the medicine is used, who is suitable, or the need for follow-up. The prescriber's judgement stays central, whoever makes the pen.

If you are curious about durability, there is a separate question people confuse with this one: whether individual pens expire. That is about shelf life, not patents, and our guides on whether Mounjaro expires and whether pens go out of date cover it. The patent and the pen expiry date are entirely unrelated.

07 · Semaglutide and tirzepatide

Semaglutide news is not tirzepatide news

Much of the coverage about weight-loss drugs coming off patent concerns semaglutide, not tirzepatide, and the two should not be confused. Competitor headlines about the first wave of generic weight-loss medicines or off-patent semaglutide refer to a different active ingredient with a different filing history and a different expiry pattern, including in different countries.

Semaglutide is the active ingredient in Wegovy and Ozempic. Wegovy pens are 0.25mg, 0.5mg, 1mg, 1.7mg and 2.4mg once weekly, with titration stepping up after at least four weeks, reaching the 2.4mg maintenance dose from week 17.¹⁸ That is a description of the licensed product, not of when its protection ends. Timelines for semaglutide vary by country.

Why does this matter to a Mounjaro patient? Because a wave of semaglutide copies in some markets can create the false impression that tirzepatide copies are imminent. They are not linked. Tirzepatide is a newer molecule, and its protection is widely understood to run later. A competitor entering the semaglutide market tells you nothing about when anyone can enter the tirzepatide market.

It also does not tell you which medicine is better for you. The decision between the two is clinical. SURMOUNT-5 was the first large head-to-head trial of tirzepatide and semaglutide for weight loss, and results from separate trials should not be set side by side as if they were head to head. If you are choosing between them, a prescriber can discuss suitability, tolerability and preference with you.

The sensible way to read any generic headline is to ask three questions: which active ingredient, which country, and whether a regulator has actually approved a product for sale. Many headlines answer none of them.

Finally, remember that a licensed generic of a different drug would not be a substitute for Mounjaro. Switching between medicines is a prescribing decision, not a pharmacy swap.

08 · What generics might mean for price

What generic competition could mean for price

Generic entry usually brings lower prices, but how much, and how fast, is unknowable today, so any figure quoted now is speculation.

Eli Lilly raised the UK list price of Mounjaro in the past, and pharmacy sell prices vary because of confidential discounts. Across the UK pharmacies we track, a Mounjaro pen currently ranges from £143.96 to £339.00 per month depending on dose and provider, checked 10 October 2026. For the 2.5mg starting pen alone, the range is £143.96 to £179.99. That spread between providers for the same dose is itself large, from £27 to £41, which means shopping around has a real effect today.

At EverydayMeds the standard price of a 2.5mg pen is £169.99 and a 15mg pen is £329.99. A new customer receives £40 off their first order at any dose with code FIRST40, and an automatic £25 reorder discount applies to every future order (code DOSE25). If you step up after 4 weeks on each dose, your first four pens (2.5mg to 10mg) cost £959.96 at standard prices before discounts. Prices checked 10 October 2026.

Why mention this on a patent page? The practical question is whether to wait for a cheaper product. Weighing it fairly, there are costs to waiting that do not show up on a price list: time without treatment, and the cost of the underlying condition continuing. Against a competitive market today, where prices already vary noticeably between providers, comparing current offers is a more reliable way to manage cost than betting on a future event.

Generics would also not necessarily bring every provider's prices down equally. Pharmacies set their own margins, and a launch period often features limited supply.

09 · NHS and private routes

NHS and private routes while you wait

Patent timelines do not govern NHS access, and the NHS route is already opening gradually. Mounjaro is available on the NHS, but access is being phased in over several years.⁴⁶

The detail matters for deciding what to do. NICE recommends it for adults with a BMI of at least 35 plus at least one weight-related condition, and the NHS primary-care rollout began in June 2025 with the highest-need groups first (initially BMI 40+ with four or more qualifying conditions).⁴⁶ Full rollout is expected to take years, which is why many people who meet the licensed criteria choose regulated private treatment rather than waiting.

A generic would not change who qualifies on the NHS, but it could change how much the NHS can afford to offer. Cheaper supply generally widens what a health service can fund. That is a reason the NHS timeline and the patent timeline are often discussed together.

If you think you might qualify, the practical step is to ask your GP what is available locally. If you do not qualify yet, or you would rather not wait for a place, private treatment is a legitimate option when it is properly regulated. The sign of a proper one is simple: a consultation with a clinician, a prescription, and dispensing by a registered pharmacy. We are registered with the GPhC under number 9012878, and anyone can check a pharmacy on the public register.

An honest framing is that the choice is not between NHS now and generic later. It is between NHS when your turn comes, private care today, or a mix. People often start privately and later move to NHS supply if they become eligible, or the reverse. Whichever you choose, treatment sits alongside diet and activity and needs regular review.

Neither route depends on the patent. Patent expiry is a market event; your treatment is a clinical decision made with a prescriber about your health, your goals and your circumstances.

10 · Should you wait, and avoiding fakes

Should you wait for a generic?

For almost everyone, waiting is not a sensible plan, because the date is uncertain and the licensed treatment is available now. The evidence for the licensed medicine is substantial. In the SURMOUNT-1 trial of 2,539 adults, people taking tirzepatide alongside diet and exercise lost on average 15% of their body weight on 5mg, 19.5% on 10mg and 20.9% on 15mg over 72 weeks, compared with 3.1% with lifestyle changes alone.² These are trial averages — individual results vary, and treatment works alongside a reduced-calorie diet and increased physical activity, not instead of them.²

That does not mean everyone should start. Whether treatment is right for you is a decision with a prescriber. But the patent calendar should not be the deciding factor.

Beware sellers claiming to offer generic Mounjaro

No licensed generic exists, so any product marketed as generic Mounjaro, cheap tirzepatide or a research-grade copy is not a licensed UK medicine. The MHRA publishes counterfeit medicine alerts and runs the Yellow Card scheme for reporting problems.⁷

Genuine pens come from the licence holder's supply chain. Ours are official LillyDirect supply, sourced directly from Eli Lilly's UK distribution, and all six doses are in stock.

How ordering works

The process is short. You complete a free online consultation, a short health questionnaire with no charge and no obligation. Payment is taken when you place the order; if the prescriber decides the treatment is not suitable, the order is refunded automatically in full. Our registered pharmacy then dispenses, with same-day dispatch when ordered by 3pm, and delivery is free next-day tracked in temperature-controlled packaging. Saturday delivery is £14.99.

If you ever stop treatment, tirzepatide has a half-life of about five days, so after a final dose it takes roughly four to five weeks to clear the system.¹ Ongoing monthly reviews are included, and repeat orders re-check suitability. Mounjaro (tirzepatide) is a prescription-only medicine, supplied only after an online consultation reviewed by a GPhC-registered prescriber. Individual results vary. This page is information, not a substitute for medical advice.